IMU

0.00%

4.8¢ imugene limited

Time for a new IMU thread!, page-26

First 26 Last

Share
Profile

Follow
Fire Bull

1,252 Posts.

19

12/03/19

21:27

Post #: 37738507
Share

Originally posted by Fire Bull: ↑

No worries, it is good to question the comparison as the mistake could easily have been mine. The study protocols can be quite intricate so it is easily done.

Agree that the path of improvement is key. However, my understanding is the last chemo treatment was day 56 so perhaps improvement we are seeing at what I think is day 98 is still the effect of chemo. I don't know if these timelines are correct for sure or if this scenario is likely.

In the Herceptin + chemo v chemo alone trial, median OS was 13.8 v 11.1 but as Axel Hoos explains in the below video, even median OS is not necessarily a good measure for evaluating immunotherapy as there may be a significant minority of patients who experience longterm benefit.

Whilst the response data we have looks like what we might expect if the treatment is working as desired, it really doesn't tell us much hence the lack of share price reaction. Now, if we get news every 84 days of continuing improvement in the data as the final patient progresses then it becomes increasingly likely that HER-vaxx works. Even no improvement in response rates but continued survival would be significant over time.

Do we know how many patients actually died to date?

First patient dosing was at the end of August in 2017 so that is more than 18 months ago. Are they still alive? How many HER-vaxx boosters has each patient had to date? Some of them could have had a few of these by now.

My understanding (although I'm not certain) is that the data we have is for all patients as at day 56 and again at day 98. If this is correct then except for the last patient, Imugene would know the status of patients beyond these periods and in some cases significantly beyond. So what has become of them? Have they continued to improve?

Expand

I said "However, my understanding is the last chemo treatment was day 56 so perhaps improvement we are seeing at what I think is day 98 is still the effect of chemo."

On rereading the study design I think chemo could continue after day 56.

IMU Price at posting: 2.0¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 32 more messages in this thread...

First 26 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$328.5K	6.792M

Buyers (Bids)

No.	Vol.	Price($)
45	5443565	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	2171910	5

View Market Depth

No.	Vol.	Price($)
45	5443565	0.048
43	4562182	0.047
49	3188200	0.046
61	6392230	0.045
12	2001364	0.044

Price($)	Vol.	No.
0.049	2171910	5
0.050	4756889	17
0.051	6179811	13
0.052	2579418	10
0.053	1158504	8

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMU (ASX) Chart

Time for a new IMU thread!, page-26

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Time for a new IMU thread!, page-26

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News